A Clinical Necessity
Improve care delivery for your Heart Failure patients
&
Reduce clinician burnout
The American College of Cardiology has a long-standing history of providing detailed guidelines backed by evidence-based research for various clinical and non-clinical factors that would affect cardiovascular care.
What’s at stake?
Heart Failure patients continue to have readmissions & low Quality of Life while studies show that clinicians encounter severe exhaustion and burnout, running from one emergency to another. A team-based approach that promotes the adoption of evidence-based research such as Guideline Directed Medical Therapy into practice is paramount at this time, both for the patient’s outcomes and for the sustainability of the healthcare system.
In the Top 10 Pivotal Issues for managing Heart Failure Patients, Guideline Directed Medical Therapy (GDMT) has been expressed to be the #1 factor to improve outcomes for cardiology patients. Research has shown that effective implementation of guideline-directed best-quality care reduces mortality, improves QOL, and preserves healthcare resources.
Despite the evidence, < 25% of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) are on the appropriate medical regimen titrated to the target doses.
What is Guideline Directed Medical Therapy (GDMT)?
Clinicians and researchers have studied the effects of various pharmacological therapies for over 30 years across different patient populations, studying their outcomes. In summary, HF guidelines have recommended the use of evidence-based angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers and mineralocorticoid receptor antagonists (MRAs), in HF patients with reduced ejection fraction (EF) (HFrEF).
This guideline-directed medical therapy (GDMT) combination (ACEI/ARB/ARNI, beta blocker, and MRA) is associated with lower all-cause mortality.
The guidelines prescribe specific therapies, initial and target dosages, up-titration schedules, and labs/parameters that need to be monitored so that the patients can be quickly titrated to their most optimal medication regimen.
What are the barriers to adopting GDMT?
One of the most important aspects of today’s care delivery is that there is a huge shortage of specialists and clinicians have less than 20 minutes of office visits per quarter with patients. During this time, there are numerous issues to consider and they don’t have a complete picture of the patient’s condition outside of the clinic setting. There is also less than suboptimal education of the patient’s condition in the limited amount of time which impacts adherence to the treatment regimen which ultimately impacts their physical health and Quality of life.
How can CueMed help?
CueMed’s clinical decision support platform is built upon the consensus of expert cardiologists chaired by the American College of Cardiology.
CueMed provides a focused and systematic effort to improve the adoption of GDMT therapies by the clinics. CueMed enrolls patients into a structured program that provides them with the devices and tools required to provide insights to the clinical team. The devices make it easy for the patients to send a continuous stream of data on key vitals such as blood pressure, heart rate, and weight to the clinical team.
CueMed continues to engage the patient using a mobile application through patient education modules, and the deployment of daily or weekly check-ins to be able to get data from the patients on their quality of life outside of the clinic setting. They are also provided notifications to be able to get appropriate labs at the appropriate time intervals so that the clinicians can monitor the clinical status and make interventions (such as adjusting up/down the medications etc)
CueMed’s clinical platform aggregates patient-generated data and provide clinicians with a risk-stratified view. The clinics can streamline their operations and provide services to the patients based on a priority scheme that can be customized by the clinic. The platform can also process the patient’s information and provide recommendations to the clinician so that the patients can be guided through an optimized medication regimen as recommended by ACC’s GDMT. The platform ensures that the algorithms are up-to-date with the current research and guideline recommendations by expert bodies such as ACC and HFSA.
Reach out to the team at CueMed to help you get started on your journey to improve care delivery to your heart failure patients & modernize the operations at your clinical practice!